Delivery Order SPE2DB24D1201-SPE2DB25FJEBX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector units valued at $1,813.90. This firm fixed-price delivery order is scheduled for completion by August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive capability...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector units valued at $1,304.29 under a firm fixed price contract. This non-set-aside delivery order, which is scheduled for completion by September 5, 2025, will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector vials valued at $3,609.99 with completion targeted for August 19, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed price terms and is performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $1,372.49 to AmerisourceBergen Drug Corp for the supply of Xyosted 100 mg/0.5 mL auto-injector units. This is a firm fixed price, competitively awarded contract with no set-aside designation, completed on August 19, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's place of performance for this federal procurement. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,532.54 on August 28, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector vials. This non-set-aside contract utilizes firm fixed price terms and requires completion by August 29, 2025, with performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,188.98 on July 22, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 23, 2025, and performance at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with DLA. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,388.60 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector (0.5 ml). This competitive award, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by August 14, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xyosted 50 mg/0.5 ml auto-injector units, valued at $1,780.19. This firm fixed-price delivery order, with an ultimate completion date of August 1, 2025, represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX, valued at $999,999,999.00 through December 2026). The order will be fulfilled from the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Xyosted 100 mg/0.5 ml auto-injector vials with a ceiling value of $1,074.75 and an ultimate completion date of August 12, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,425.66 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector pharmaceutical products. This firm fixed price, competitively awarded delivery order was issued on August 25, 2025, with an ultimate completion date of August 26, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJEBXDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector doses valued at $1,095.14. This firm fixed-price delivery order, with an ultimate completion date of September 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract was competitively awarded with no set-aside designation, and performance will be executed from the vendor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor specializing in pharmaceutical products and medical supplies for military and veteran healthcare systems. The company's DLA Troop Support Medical contract serves as a comprehensive global pharmaceutical support vehicle enabling the supply of brand-name and generic medications, vaccines, medical devices, and specialty pharmaceuticals across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/4/25 |